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A
mAbstract
As evidenced by high-throughput sequencers, genomic technologies have recently
undergone radical advances. These technologies enable comprehensive sequencing
of personal genomes considerably more efficiently and less expensively than
heretofore. These developments present a challenge to the conventional framework
of biomedical ethics; under these changing circumstances, each research project
has to develop a pragmatic research policy. Based on the experience with a new
large-scale project—the Genome Science Project—this article presents a novel
approach to conducting a specific policy for personal genome research in the
Japanese context. In creating an original informed-consent form template for
the project, we present a two-tiered process: making the draft of the template
following an analysis of national and international policies; refining the draft
template in conjunction with genome project researchers for practical application.
Through practical use of the template, we have gained valuable experience in
addressing challenges in the ethical review process, such as the importance of
sharing details of the latest developments in genomics with members of research
ethics committees. We discuss certain limitations of the conventional concept of
informed consent and its governance system and suggest the potential of an
alternative process using information technology.
Keywords: ELSI; Personal genomics; Informed consent; E-governanceIntroduction
The completion of the Human Genome Project (HGP) has brought about a dramatic ad-
vance in the life sciences, especially genomics (International Human Genome
Sequencing Consortium 2004; Green et al. 2011). Recent genomics research has pro-
duced large quantities of personal genome data by means of next-generation sequencers
and information-analysis techniques (Mardis 2011; Shendure and Aiden 2012). These
technological developments have enabled international research projects to sequence per-
sonal genomes on a massive scale, such as the 1000 Genomes Project (The 1000
Genomes Project Consortium 2010) and the International Cancer Genome Consortium
(ICGC) (The International Cancer Genome Consortium 2010). In these projects, re-
searchers are required to work together cooperatively and effectively, and they then share
the personal genome data internationally (Clarke et al. 2012; Joly et al. 2012). In addition,2014 Minari et al.; licensee Springer. This is an Open Access article distributed under the terms of the Creative Commons
ttribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any
edium, provided the original work is properly cited.
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level, including the United States, the United Kingdom, China, and Japan.
The coming of the personal genome era brings the possibility of personalized medi-
cine based on the individual genome; however, at the same time, it raises concerns
about ethical, legal, and social implications (ELSI) (Caulfield et al. 2008), which require
further consideration. As the sequenced and analyzed data become ever larger and sig-
nificantly more complex, research participants face greater difficulty in understanding
the contents of a study and their own rights, benefits, and risks. In this regard, many
reports have addressed several key topics, such as informed consent, data sharing, and
returning results (McGuire et al. 2008; Kaye et al. 2010; Tabor et al. 2011). These pro-
posals and recommendations can be informative and useful in developing a framework
for a research policy in personal genome research. For practical purposes, however,
each research project and organization naturally has to create concrete policies based
on the scientific, social, and cultural context in which the study is being conducted.
In Japan, some national projects have been promoted in addition to such inter-
national projects as the HGP, the International HapMap Project (The International
HapMap Consortium 2005), and the ICGC. Those national projects have been funded
mainly by the Ministry of Education, Culture, Sports, Science and Technology (MEXT)
and the Ministry of Health, Labour and Welfare (MHLW). One such longstanding pro-
ject is the MEXT-funded Biobank Japan Project, which is a disease-focused biobanking
project that has collected DNA, sera, and clinical data since 2003 from more than
200,000 patients with one of 47 common diseases (Nakamura 2007).
Another long-established project funded by MEXT has operated since around 1990.
That project recently completed its fourth stage, having changed both its name and
purpose at each stage. Initially, this project specifically addressed the progress of the
HGP; gradually, it advanced along various avenues in genomic research, including plant
and animal genomes and bioinformatics, while considering the relationship between
genome research and society (Itoh and Kato 2005). The fifth stage of the project,
named the Genome Science Project (GSP), started in 2010. The GSP aims to support
various genome researchers in Japan who are funded by MEXT and selected through
an annual open call; it does so by providing the services of high-throughput DNA se-
quencing and high-grade information technology. From 2010 to 2013, the GSP notably
supported 300 individual research projects proposed by genome researchers.
As shown in Figure 1, the GSP consists of four subgroups. One of these is the Medical
Genome Science Program (MGSP), which carries out whole human genome and exome
sequencing and associated bioinformatic analysis. The MGSP also aims to create a Japa-
nese reference genome, and it shares genome data through national public databases,
such as the DNA Data Bank of Japan (Kosuge et al. 2013) and the Human Genome Vari-
ation Database (Koike et al. 2009). To address the ELSI of these actions, a specific group
called the Research Unit for the ELSI of Genomics has been established within the GSP.
As indicated in Figure 2, this research unit is tasked with crafting research policy and exe-
cuting two ethical tasks (ethical review of documents submitted by the applicants and
responding to inquiries regarding the ethical review process) in the MGSP workflow.
Based on a consideration of the Japanese context, we describe in this article the approach
and experience in formulating the research policy of the GSP—especially with regard to a
suitable informed consent form (ICF) for personal genome research.
Figure 1 Organizational chart of the GSP, which consists of four parts: Overview Group; Large-Scale
Genome Information Production Program; Medical Genome Science Program (MGSP); and Bioinformatics
Analysis Program. Genome researchers who receive funding from the MEXT can apply to the GSP, and
researchers selected through open call can receive research support. Additionally, the sequenced data
obtained by the GSP are in principle entered into national and public databases.
Minari et al. Life Sciences, Society and Policy 2014, 10:4 Page 3 of 11
http://www.lsspjournal.com/content/10/1/4Concept of informed consent and making a model ICF
The idea of informed consent has been a fundamental norm in medical ethics since the
mid-twentieth century, as evident in the Nuremberg Code (US Government Printing
Office 1949) and the related Declaration of Helsinki (World Medical Association 1964).
Initially, informed consent was introduced as a mechanism to ensure that the partici-
pant adequately understood the scope and content of agreements, such as the purpose
of the enterprise, status regarding free participation and withdrawal, and risks andFigure 2 Schematic illustration of the workflow system in the MGSP and the function of the
research unit for the ELSI of genomics for the MGSP. The applicant has to submit three documents to
the MGSP: the research protocol, the informed consent form (ICF), and the MGSP application proposal. After
review, both the selected researchers and associated members of the MGSP need to receive approval from
the research ethics committees (RECs) of the relevant institutions. Then, the researchers have to obtain
informed consent (IC) from the participants and send the specimens to the MGSP. Accordingly, the MGSP
sequences and analyzes the samples; it then returns these data to the researchers, and it also enters the
results into national and public databases. Here, the unit crafts the ICF template and its policy, evaluates the
ethical aspects of the documents in an open-call process, and also responds to ethical inquiries
from researchers.
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lations. Since then, the notion of informed consent has supported the right of partici-
pants in self-determination, and the scope of its application has expanded alongside the
dramatic advances in biomedical and clinical research.
In human genomic research, however, the concept of informed consent differs some-
what from the original concept in certain respects. Genomic research basically uses hu-
man specimens with less invasive methodologies, and it focuses on genomic
information, which affects not only the participant, but also family members and re-
lated populations (Kaye et al. 2010). Additionally, recent personal genome research has
covered whole-genome information, including functionally unrevealed genome se-
quences, and it thus poses more unexpected risks to the participants. Moreover, al-
though biobanking of human specimens and data sharing of personal genome data are
currently conducted to facilitate further research, they potentially involve many more
issues in terms of privacy and unlimited future uses of samples and data; these are the
secondary, multipurpose uses by various researchers. As a result, the function of in-
formed consent has become increasingly diversified in personal genome research.
Biomedical research in Japan is subject to soft regulation through numerous subdi-
vided guidelines, with the exception of some areas such as drug trials (Tashiro 2010).
For human genome and genetic research, in addition to the Fundamental Principles of
Research on the Human Genome released in 2000 (Bioethics Committee, Council for
Science and Technology 2000), national guidelines exist known as the Ethical Guide-
lines for Human Genome/Gene Analysis Research, which were prepared by three min-
istries in 2001—MEXT, MHLW, and the Ministry of Economy, Trade and Industry
(MEXT, MHLW and METI 2001). Although they are not legally binding, they have
strong influence over the ethical conduct of research. The 2001 guidelines describe
basic principles and various issues including the method of informed consent, the re-
turn of results, and handling of samples. However, although the guidelines address gen-
eral procedures, they do not detail specific instructions for each project and research
institution (Slingsby et al. 2004). Especially, in the section on informed consent in the
guidelines, although several subsidiary rules are listed for preparing the ICF, they can-
not be readily associated with the concrete standard model of an ICF for Japan; thus,
each research institute and project has to design the document independently. Further-
more, the guidelines do not deal with current conditions of personal genome research
or data sharing.
In this context, we created a model ICF template for the MGSP. In the process, we
had to consider major ethical issues related to personal genome research, such as data
sharing and the returning of results, as detailed in other studies (Caulfield et al. 2008).
Notably, the MGSP supports personal genome research at institutes across Japan, and
it imposes the sharing of personal genome data on supported researchers. However,
broad data sharing was previously little practiced in Japan, and it requires careful de-
sign of the ICF template, which specifically means an adequate, appropriate description
of the data sharing.
In making the model ICF template, we surveyed existing informed consent docu-
ments. These were mainly collected from medical schools in Japan, as well as from
international projects such as the 1000 Genomes Project, the ICGC, and the Public
Population Project in Genomics. We referred to the research policies of funding
Minari et al. Life Sciences, Society and Policy 2014, 10:4 Page 5 of 11
http://www.lsspjournal.com/content/10/1/4agencies abroad, including those of the National Institutions of Health and Wellcome
Trust. From a comparison of approximately 20 documents related to Japan, however,
most did not assume a research application for the personal genome. Combining the
advantages of these domestic documents and foreign documents and policies that in-
corporated personal genome research, we came up with a draft of a model ICF tem-
plate for the MGSP that was in accordance with both Japanese government guidelines
and international norms and guidelines. We believed that this approach would be bene-
ficial in formulating a national standard that adhered to international standards.
To refine the draft of the ICF template, we held repeated discussions with execu-
tive genome researchers of the MGSP and GSP. Those individuals were representa-
tive of genome researchers in Japan and included physicians, research scientists, and
bioinformaticians. The discussions were conducted over a period of 2 months in
2010 in two ways: face-to-face communication at an executive board meeting and
online communication by means of an e-mail-based forum. The executive board
meeting had the function of identifying controversial ethical topics in the draft of
the ICF template and outlining the basic direction to be taken in that regard. The e-
mail-based forum played a role in concrete considerations related to the ICF tem-
plate and involved detailed, specific modifications to the document. This system
worked effectively toward rapidly reaching a consensus on research policy within
the MGSP: the leaders of the MGSP and GSP actively took part in the process and
increasingly recognized the importance of ethical aspects in personal genome re-
search. In addition, the cooperation with genome researchers was invaluable for in-
corporating pragmatic aspects of research.
The consensus regarding the research policy of the ICF template for MGSP appli-
cants consisted of the following five key issues (Table 1): research purpose; collabor-
ation with external institutes; data sharing; withdrawal of consent; and risk assessment
and management. For a sixth key issue—returning research results and incidental find-
ings—clear consensus could not be achieved. With regard to data sharing, there were
notable difficulties in effecting an appropriate system since this was the first attempt to
introduce two access levels (open-access and controlled-access levels) into informed-Table 1 Specific requirements of the IC document to the MGSP
Key issues Description
Research purpose  Explanation of personal genome research
 Description of whole-genome/exome sequencing, if applicable
 Description of general research purposes of genotype-phenotype information
Collaborations with
external institutions
 List of names of relevant institutions and principle investigators in the MGSP
Data sharing  Description of significance and purpose of data sharing
 Two levels of access to national/public databases
Withdrawal of
consent





 Explanation of associated ethical, legal and social issues
 Genetic counseling
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generally used for genotype and phenotype databases (Mailman et al. 2007; The Inter-
national Cancer Genome Consortium 2010), is different from open access: controlled
access requires the database user to obtain prior permission or authorization from an
appropriate committee when browsing or downloading registered data. Although in-
corporating this two level access system into the ICF template has the potential draw-
back of producing a complex, confusing situation for researchers, research ethics
committee (REC) members, and research participants, we adopted this approach so as
to obtain support for the basic notion of data sharing through public databases and to
provide information on the type and range of the shared data.
As noted above, we were unable to reach clear consensus about the returning of re-
sults. Indeed, the disclosure of individual research results to participants is one of the
most controversial areas in the ELSI of personal genomics (Knoppers et al. 2006; Wolf
et al. 2008, 2012; McGuire and Lupski 2010; Levesque et al. 2011). In Japan, while there
are national guidelines for human genome research, as described above, these leave de-
cisions to the broad discretion of researchers. In our discussions with MGSP and GSP
members, we learned that in Japan most personal genome studies—but not personal
genome testing and analysis services—aim toward an understanding of the causes and
mechanisms of diseases. Owing to the breadth of their purpose, such genome studies
have little meaningful information that could be returned immediately to the partici-
pants. Furthermore, we confirmed at this point that the disclosure of research results
for clinical purposes, but not incidental findings (an area still under consideration), was
beyond the scope of the original research purposes. As a result, it was believed that
such disclosure was not an obligation or responsibility on the part of investigators, in
addition to the fact that data accuracy obtained in most basic research is generally not
sufficiently high to qualify as clinical grade. Finally, after consideration of various re-
search projects supported by the MGSP, we decided to leave the decision in this matter
to each MGSP applicant.
In the finalized ICF template, which reflects the research policy of the MGSP, we
were able to identify unique or specific characteristics related to Japanese society. First,
the ICF template places a particular emphasis on accurately corresponding to develop-
ments in genome research, its purpose, and the risks for research participants. This is
largely the result of historical issues in Japan related to social discrimination and
stigmatization through inheritable diseases (Triendl and Gottweis 2008; Porter 2009).
In some cases, such discrimination and stigmatization could lead to a negative image of
genome research among the Japanese public. Second, the template comprehensively
describes handling procedures of personal information and individual genetic informa-
tion of research participants. This move is associated with the growing concern for
privacy among the Japanese public after the enactment of the Act on the Protection of
Personal Information of 2003 (Act No. 57 of 2003; Triendl and Gottweis 2008; Porter
2009; Masui 2009). This concern could lead to over-sensitivity to misuse of information
on the part of research participants—even with regard to the use of information in bio-
medical research. Third, the template underlines the necessity to establish a robust re-
lationship with research participants in the documentation process. This adjustment
arose because several incidents occurred in Japan in around the year 2000, whereby a
large number of samples were analyzed without informed consent having been obtained
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sistent reluctance and skepticism on the part of participants to genome research.
In the case of applicants who wish to use existing samples, and thus do not need to
employ the ICF template, we decided—after much debate—to adopt the same require-
ment conditions detailed above, i.e., the conditions for applicants using existing sam-
ples would be the same as those for applicants with new samples. Thus, if applicants
with existing samples did not meet the requirements, they would have to obtain add-
itional consent. Although requiring consent in this manner in the case of using existing
samples places rather heavy demands on applicants, our decision resulted from a con-
sideration of the participants: personal genome research and associated data sharing
potentially have unexpected risks owing to the unfocused nature of whole-genome and
exome sequencing and reidentifiability from data sharing (Rodriguez et al. 2013).
Challenges facing the use of the ICF template and its prospects in Japan
The greatest challenge for the implementation of our project was whether the ICF tem-
plate would be acceptable to the RECs of the institutes across Japan with which MGSP
applicants are associated. Even if a model ICF could be created for research partici-
pants, it would be practically meaningless without approval by the RECs under the
current ethical framework. As reported in previous papers, different RECs may evaluate
the same protocol variously and apply the regulations in a different way (Silverman
et al. 2001; Silberman and Kahn 2011). In Japan, while the governmental guidelines
provide discretion and responsibility to RECs, they do not necessarily provide proced-
ural details regarding the evaluation (Slingsby et al. 2004; Porter 2009). In addition, un-
like other countries, there are no widely-used accreditation programs or centralized
research ethics committee to review multicenter studies (Burman et al. 2001; Emanuel
et al. 2004; Coleman and Bouësseau 2008). These issues make the outcome of the
ethical review even more uncertain than those in countries with such programs and
systems. Indeed, we found that several investigators supported by the MGSP did en-
counter some difficulties in obtaining REC approval. To address this problem, we im-
plemented the following two measures.
One was that we developed requirement lists for the research proposal and for the in-
formed consent document to be given to MGSP applicants. The lists detailed the infor-
mation that applicants had to enter in the application documents. The need for the list
for the research proposal arose from the experience that in such proposals to REC
members, MGSP-supported researchers often failed to provide sufficient information
about the GSP and MGSP—especially concerning their purpose and significance and
the concrete details of personal genome analysis and data sharing. The need for the list
regarding informed consent developed because supported researchers often mistakenly
incorporated the research policy of the MGSP into the informed consent document of
their institution—not the ICF template provided by the MGSP. These two requirement
lists served as a practical and powerful means of reliably informing researchers of the
minimum requirements for those documents and then appropriately providing the ne-
cessary information to REC members.
The second measure was that we held a workshop regarding ethical review of per-
sonal genome research (August 2012 in Tokyo). Even if researchers support the use of
the research proposal and informed consent documents containing the research policy
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ther facilitate the ethical review process, we requested participation in the workshop by
REC members and support staff of all research institutions to which the supported re-
searchers belonged. In total, 76 people from 30 institutes participated in the workshop,
during which we explained the current situation of personal genome research and data
sharing in addition to the activities of the GSP and MGSP. Through this experience, we
found that such workshops are useful in facilitating the sharing of current information
and basic rules for the ethical review of personal genome research; regular workshops
can also be used to coordinate and improve the quality of ethical review of multicenter
studies.
We made several important findings with this practical use of the ICF template. The
first is the necessity to rapidly share knowledge related to the latest genome research
among professionals, such as researchers and REC members. The second is the neces-
sity to foster a robust collaboration between professionals from different fields for pro-
moting large-scale projects. In this regard, we found that if relevant professionals in
Japan are aware of the challenges related to such projects, they are often more willing
to collaborate. This situation may reflect the characteristics of Japanese culture; thus, it
may be a desirable strategy to effect such collaboration to facilitate ethically sound
research.
The most important finding for us regarding the practical use of the ICF template
was the necessity to review the concept of conventional informed consent and the eth-
ical governance system. For the governance of genome research using human speci-
mens, the “one researcher, one project, one jurisdiction” model, whose origins are in
the Nuremberg Code, has been widely adopted (Kaye 2011). With this model, informed
consent is on a one-time basis and mostly front-loaded (Gostin and Hodge 1999). Ac-
cordingly, the system of traditional informed consent and RECs faces greater challenges
in personal genome research. In particular, there are difficulties with the prior one-time
consent approach being able to fully inform research participants of broad research
plans because “the more general the consent is, the less informed it becomes” (Arnason
2004). With this project in Japan, we learned the limitation of incorporating ethical
considerations in prior one-time consent because it is difficult to anticipate the future
scope of research, including data sharing and the risks and benefits of whole-genome
and exome sequencing. Several reports have suggested the necessity of additional or al-
ternative procedures without relying solely on the conventional informed consent pro-
cedure (Caulfield et al. 2008; Lunshof et al. 2008; Watanabe et al. 2011; Kaye 2011).
The introduction of digitalization to the system—e-governance—is attracting atten-
tion as a means of establishing a strong relationship among stakeholders. Information
technology (IT)-based consent, sometimes called dynamic consent (McGuire and Bes-
kow 2010; Kaye et al. 2012), allows more continuous, flexible, and interactive imple-
mentation than the conventional one-time consent. This IT approach regards
participants as a kind of partner, and through a Web-based infrastructure it provides
them with multiple opportunities to make decisions regarding research participation.
The IT infrastructure could also provide an effective supplementary tool for informed
consent: it can be used to create an online community for continuous connection
among researchers, bioresources, and research participants (Cambon-Thomsen et al.
2011; Fenner et al. 2011). The online system for returning results called My46 (Tabor
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governance approach still faces several technical, financial, and social issues in terms of
its feasibility and public acceptability, it will undoubtedly play a significant role in re-
specting the flexible autonomy of research participants and lightening the future man-
agement load of researchers and REC members.
Finally, we have described in this article personal genome research policy, but not
clinical practice. Recently, many major institutions have already started using whole-
genome and exome sequencing in the clinical setting (Worthey et al. 2011; Bainbridge
et al. 2011; Gonzaga-Jauregui et al. 2012). As a result, the discussion of the ELSI associ-
ated with clinical practice is becoming more heated (Biesecker et al. 2012). In Japan,
there are some such activities in clinical application, albeit on a much smaller scale.
Our experience with research policy may share a number of similarities with the situ-
ation in clinical practice, and our findings may serve at least as a starting point for
policy-making activities in the clinical setting.Conclusion
We have presented a research policy and approach for the GSP. We reconsidered the
nature of informed consent, developed an ICF template, and aimed to facilitate an un-
derstanding of the project’s policy among researchers and REC members. Formulating
the ICF template taught us the difficulty in setting a specific policy regarding data shar-
ing and returning results, and we noted the specific ethical characteristics of informed
consent in Japan. With the practical use of the template, we found that sharing the lat-
est knowledge about genome research and collaboration among various professionals
were important in promoting a large-scale project that involves many research insti-
tutes. Furthermore, our experience provided an opportunity to reconsider the nature of
one-time consent and the research governance system. To solve the attendant problems
without resorting to the consent approach, it will be necessary to reevaluate the con-
ventional governance system. Among several possibilities, the use of an IT-based gov-
ernance system would appear to be effective in enabling dynamic communication with
research participants. As an increasing number of IT-based methods are developed and
become adopted, it will be possible to establish a well-balanced research governance
system that can incorporate both participants’ trust and research advancement.
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